TA-ASSOCIATES
Francisco Partners (“FP”) and TA Associates (“TA”), leading global investment firms, announced today that they have signed an agreement to become co-controlling shareholders of Orisha, a leading European vertical software company based in France. TA, Orisha’s majority shareholder since 2021, will reinvest in the Company alongside Francisco Partners and Orisha management. The investment will allow Orisha to further advance its growth journey, solidifying its industry leadership through ongoing organic growth, diversification, geographic expansion and strategic acquisitions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716551941/en/
Headquartered in Paris, Orisha, formerly known as DL Software, was established in 2003 to bring industry-specific ERP software to a variety of end markets in France. The Group now employs over 1,800 people and offers highly specialized vertical software solutions to over 40,000 customers. Previously supported by 21 Invest France, which is now a minority investor, Orisha has grown revenue by approximately four times and transformed its operating model since TA’s initial investment in 2021, consolidating more than 25 independent business lines into five vertically focused business units: Retail, Health & Safety, Construction, Real Estate and Agri-Food. These business units are now supported by centralized functional teams for finance, HR and technology infrastructure. With over €250 million of revenue expected this year, Orisha’s strategic objective is to offer high-quality and agile software solutions to customers by maintaining customer proximity, accelerating technological innovation and increasing organizational integration.
Jacques Ollivier, CEO of Orisha said, “We are thrilled to onboard Francisco Partners alongside TA as we aim to drive continued growth and further enhance Orisha’s offerings. Both TA and Francisco Partners share our vision for the Company, and we are excited to work together to ensure sustained strong performance in the future. With their support, Orisha is positioned for expansion and to provide our customers with the best solutions.”
“Since our initial investment three years ago, Orisha has experienced meaningful growth and positive transformation under the direction of Jacques and the entire leadership team. We remain deeply confident in the Company’s long-term organic and inorganic growth potential, and we look forward to collaborating with Francisco Partners for the next chapter of Orisha’s journey,” said Maxime Cancre, Director, and Patrick Sader, Managing Director, at TA.
“We are big believers in the power of vertical software and hence fully aligned with Orisha’s mission and vision to build industry-specific solutions. Having tracked the company closely for years, we have been impressed by all that the Orisha team has accomplished, under the leadership of Jacques. Working in partnership with him and TA, we will seek to support Orisha’s next stage of growth by continuing to serve its loyal customer base and expanding thoughtfully into new segments,” said Quentin Lathuille, Principal, and Petri Oksanen, Partner and Co-Head of European Investing, at Francisco Partners.
J.P. Morgan acted as exclusive financial advisor and Latham and Watkins acted as legal advisor to TA. Bryan Garnier acted as financial advisor and Paul Hastings acted as legal advisor to Francisco Partners.
The transaction remains subject to regulatory and antitrust approvals and is expected to close in Q4 2024. Financial terms of the transaction were not disclosed.
About Orisha
Founded in 2003, Orisha is a European software publisher dedicated to companies in the retail, real estate, healthcare, construction and agri-food sectors. Since its creation, Orisha has been helping companies to succeed by offering them solutions tailored to their business needs and essential to their activity (cash collection, commercial and financial management, stock management, CRM, HR, unified commerce…). Each day, Orisha’s solutions facilitate millions of interactions and transactions in a hyper-connected world. Since 2021, Orisha has been backed by TA Associates, a global private equity player and leader in the technology sector. In 2023, Orisha achieved sales in excess of €200m. The group, which was born in France, employs 1,800 people in Europe and supports clients in over 50 countries. More information: https://www.orisha.com
About Francisco Partners
Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch 25 years ago, Francisco Partners has invested in more than 450 technology companies, making it one of the most active and longstanding investors in the technology industry. With approximately $45 billion in capital raised, the firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential. For more information on Francisco Partners, please visit www.franciscopartners.com.
About TA
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has over 150 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. For more information, visit www.ta.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716551941/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom